Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
Kyverna Therapeutics says long-term data support an FDA submission for its CAR T therapy in a rare autoimmune disease.
Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing autologous and allogeneic CAR T-cell therapies for autoimmune diseases. Kyverna is poised to become the first company to file a regulatory application for a CAR T-cell therapy in autoimmune disease.
Company Info
Upcoming Milestones & Key Dates
2026 H2
Regulatory
First regulatory filing for CAR T in autoimmune disease
Q4 2026
Clinical
Additional autoimmune disease readouts
Clinical Development Pipeline
KYV-101
Target: CD19 CAR-TKYV-101
Target: CD19 CAR-TKYV-201
Target: Allogeneic CD19 CAR-TRecent News
Leadership Team
Ian Anderson
Chief Executive Officer
Dominic Borie
Chief Medical Officer
To be confirmed
Chief Scientific Officer